eVOLVE-Lung02

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Aug 11, 2023 → Oct 29, 2026

Cited window

Aug 11, 2023 → Aug 24, 2026

Retrieved

Oct 29, 2026

Title

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Registry

NCT05984277

Study IDs

D798AC00001 · 2023-000056-38

Sponsor

AstraZeneca

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

895 actual

Start

2023-10-24 actual

Primary completion

2026-08-17 actual

Primary endpoint

Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –44 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of HCP opinion; source totals should not be read as numbers of independent clinicians.
• –The sources do not include a full protocol or an eVOLVE-Lung02 results publication. Announcement-based interpretations cannot establish numerical efficacy, detailed comparative safety or the reason for futility.
• –The episode's individual speakers are not identified in the transcript, so its views cannot be attributed to the named hosts.
• –The earlier phase 1b response and treatment-related-death comments concern a different study, and the relevant post is truncated.
• –Access statements describe the March 2024 discussion and do not establish current or uniform availability across countries.
• –Clinical roles are not confirmed for every named author. Strategic and investor-oriented observations should not be treated as HCP consensus.
• –Not yet captured in this edition: a view on the monitoring committee’s assessment of first-line treatment efficacy in metastatic lung cancer.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "eVOLVE-Lung02" (NCT05984277), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "evolve-lung02-05984277". If you cannot make requests, read https://www.erudio.com/reports/evolve-lung02-nct05984277.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05984277", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05984277 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/evolve-lung02-nct05984277.json
curl https://www.erudio.com/reports/evolve-lung02-nct05984277.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "evolve-lung02-05984277" })